Search Results - "Van Dyck, C"

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease by Salloway, S, Sperling, R, Gilman, S, Fox, N C, Blennow, K, Raskind, M, Sabbagh, M, Honig, L S, Doody, R, van Dyck, C H, Mulnard, R, Barakos, J, Gregg, K M, Liu, E, Lieberburg, I, Schenk, D, Black, R, Grundman, M

“…Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple…”
Get full text

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease by SANO, M, BELL, K. L, GALASKO, D, GALVIN, J. E, THOMAS, R. G, VAN DYCK, C. H, AISEN, P. S

“…Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies…”
Get full text

Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies by Harrington, C, Sawchak, S, Chiang, C, Davies, J, Donovan, C, Saunders, A M, Irizarry, M, Jeter, B, Zvartau-Hind, M, van Dyck, C H, Gold, M

“…Two phase 3 studies evaluated the efficacy and safety of rosiglitazone (RSG), a type 2 diabetes treatment, in an extended release (RSG XR) form as adjunctive…”
Get more information

HOMO Level Pinning in Molecular Junctions: Joint Theoretical and Experimental Evidence by Rodriguez-Gonzalez, S, Xie, Z, Galangau, O, Selvanathan, P, Norel, L, Van Dyck, C, Costuas, K, Frisbie, C. D, Rigaut, S, Cornil, J

“…A central issue in molecular electronics in order to build functional devices is to assess whether changes in the electronic structure of isolated compounds by…”
Get full text

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease by SALLOWAY, S, SPERLING, R, CRANS, G, LIANG, E, QUINN, G, BAIRU, M, PASTRAK, A, CEDARBAUM, J. M, KEREN, R, PORSTEINSSON, A. P, VAN DYCK, C. H, TARIOT, P. N, GILMAN, S, ARNOLD, D, ABUSHAKRA, S, HERNANDEZ, C

“…This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid…”
Get full text

Racial/Ethnic, Socioeconomic, and Behavioral Determinants of Childhood and Adolescent Obesity in the United States: Analyzing Independent and Joint Associations by Singh, Gopal K., PhD, Kogan, Michael D., PhD, Van Dyck, Peter C., MD, MPH, Siahpush, Mohammad, PhD

“…Purpose This study examines independent and joint associations between several socioeconomic, demographic, and behavioral characteristics and obesity…”
Get full text

Growth hormone secretagogue MK-677 : No clinical effect on AD progression in a randomized trial by SEVIGNY, J. J, RYAN, J. M, VAN DYCK, C. H, PENG, Y, LINES, C. R, NESSLY, M. L

“…In animals, insulin-like growth factor-1 (IGF-1) increases clearance of beta-amyloid, a pathologic hallmark of Alzheimer disease (AD), from the CNS. Serum…”
Get full text

A National Profile of the Health Care Experiences and Family Impact of Autism Spectrum Disorder Among Children in the United States, 2005-2006 by Kogan, Michael D, Strickland, Bonnie B, Blumberg, Stephen J, Singh, Gopal K, Perrin, James M, van Dyck, Peter C

“…We sought to examine the health care experiences of children with autism spectrum disorder and the impact of autism spectrum disorder on the family and to…”
Get full text

Prevalence of Parent-Reported Diagnosis of Autism Spectrum Disorder Among Children in the US, 2007 by Kogan, Michael D, Blumberg, Stephen J, Schieve, Laura A, Boyle, Coleen A, Perrin, James M, Ghandour, Reem M, Singh, Gopal K, Strickland, Bonnie B, Trevathan, Edwin, van Dyck, Peter C

“…The reported increasing prevalence of autism spectrum disorder (ASD) and attendant health and family impact make monitoring of ASD prevalence a public health…”
Get full text

A vision of the future of newborn screening by Alexander, Duane, van Dyck, Peter C

“…In 40 years, newborn screening has evolved to become a standard component of preventive public health. Despite its widespread acceptance, efforts need to be…”
Get full text

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease by Budd Haeberlein, Samantha, Aisen, P.S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., Iwatsubo, T., Mallinckrodt, C., Mummery, C.J., Muralidharan, K.K., Nestorov, I., Nisenbaum, L., Rajagovindan, R., Skordos, L., Tian, Y., van Dyck, C.H., Vellas, B., Wu, S., Zhu, Y., Sandrock, A.

“…Background Alzheimer’s disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in…”
Get full text

Increased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort by Abi-Dargham, Anissa, Gil, Roberto, Krystal, John, Baldwin, Ronald M., Seibyl, John P., Bowers, Malcom, van Dyck, Christopher H., Charney, Dennis S., Innis, Robert B., Laruelle, Marc

“…OBJECTIVE: The authors previously observed an increase in striatal dopamine transmission following amphetamine challenge in 15 untreated patients with…”
Get full text

Reduced brain serotonin transporter availability in major depression as measured by [ 123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography by Malison, Robert T, Price, Lawrence H, Berman, Robert, van Dyck, Christopher H, Pelton, Gregory H, Carpenter, Linda, Sanacora, Gerard, Owens, Michael J, Nemeroff, Charles B, Rajeevan, Nallakandi, Baldwin, Robert M, Seibyl, John P, Innis, Robert B, Charney, Dennis S

“…Background: Prior research has suggested reductions in the density of serotonin transporter (SERT) binding sites in blood platelets and post-mortem brain…”
Get full text

Independent and Joint Effects of Socioeconomic, Behavioral, and Neighborhood Characteristics on Physical Inactivity and Activity Levels Among US Children and Adolescents by Singh, Gopal K., Kogan, Michael D., Siahpush, Mohammad, van Dyck, Peter C.

“…This study examines the independent and joint associations between several socioeconomic and behavioral characteristics and physical activity (PA) and…”
Get full text

The Alpha-2A-Adrenoceptor Agonist, Guanfacine, Increases Regional Cerebral Blood Flow in Dorsolateral Prefrontal Cortex of Monkeys Performing a Spatial Working Memory Task by Avery, Robert A, Franowicz, Jenna S, Studholme, Colin, van Dyck, Christopher H, Arnsten, Amy F.T

“…Research indicates that norepinephrine enhances the working memory functions of the prefrontal cortex (PFC) through actions at post-synaptic, alpha-2A…”
Get full text

SPECT Imaging of Striatal Dopamine Release after Amphetamine Challenge by Laruelle, Marc, Abi-Dargham, Anissa, van Dyck, Chris H, Rosenblatt, William, Zea-Ponce, Yolanda, Zoghbi, Sami S, Baldwin, Ronald M, Charney, Dennis S, Hoffer, Paul B, Kung, Hank F, Innis, Robert B

“…This study assesses the feasibility of using SPECT to image intrasynaptic dopamine release in human striatum following dextroamphetamine sulfate…”
Get full text

New Photomechanical Molecular Switch Based on a Linear π‑Conjugated System by Lenfant, S, Viero, Y, Krzeminski, C, Vuillaume, D, Demeter, D, Dobra, I, Oçafrain, M, Blanchard, P, Roncali, J, Van Dyck, C, Cornil, J

“…We report the electron-transport properties of a new photoaddressable molecular switch. The switching process relies on a new concept based on linear…”
Get full text

Iodine- 123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients by SEIBYL, J. P, MAREK, K, SHEFF, K, ZOGHBI, S, BALDWIN, R. M, CHARNEY, D. S, VAN DYCK, C. H, INNIS, R. B

“…Iodine-123-beta-carbomethoxy-3 beta-(4-iodophenyltropane) (CIT) has been used as a probe of dopamine transporters in Parkinson's disease patients using SPECT…”
Get full text

Age-related decline in central serotonin transporter availability with [ 123I]β-CIT SPECT by van Dyck, Christopher H, Malison, Robert T, Seibyl, John P, Laruelle, Marc, Klumpp, Heide, Zoghbi, Sami S, Baldwin, Ronald M, Innis, Robert B

“…Postmortem studies have provided limited and conflicting data regarding aging effects on the central serotonin transporter (SERT). The present study…”
Get full text

[123I]β-CIT SPECT imaging assessment of the rate of Parkinson's disease progression by MAREK, K, INNIS, R, VAN DYCK, C, FUSSELL, B, EARLY, M, EBERLY, S, OAKES, D, SEIBYL, J

“…[123I]beta-CIT and SPECT imaging of the dopamine transporter is a sensitive biomarker of PD onset and severity. In this study, the authors examine the change…”
Get full text